GSK flashes positive data for Tesaro drug that could become 7th approved PD-(L)1
A dark horse asset from GlaxoSmithKline’s $5.1 billion buyout of Tesaro is out with its first batch of data in over a year — promising data that could line up the British drugmaker for the 7th FDA approved PD-1 drug, although it’s not clear when.
When GSK purchased the Waltham-based cancer biotech in December of 2018, conversation focused rightly on Zejula, the already-approved PARP inhibitor, and whether the new executive crew of Hal Barron and Emma Walmsley were right in their assertion that the drug could both rival AstraZeneca’s Lynparza and have utility in more than just ovarian cancer. But Tesaro also brought a couple of other clinical stage assets. Chief among them: a PD-1 inhibitor called dostarlimab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.